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We have used a supervised classiﬁcation approach to systematically mine a large microarray
database derived from livers of compound-treated rats. Thirty-four distinct signatures (classiﬁers)
for pharmacological and toxicological end points can be identiﬁed. Just 200 genes are sufﬁcient to
classify these end points. Signatures were enriched in xenobiotic and immune response genes and
contain un-annotated genes, indicating that not all key genes in the liver xenobiotic responses have
been characterized. Many signatures with equal classiﬁcation capabilities but with no gene in
common can be derived for the same phenotypic end point. The analysis of the union of all genes
present in these signatures can reveal the underlying biology of that end point as illustrated here
using liver ﬁbrosis signatures. Our approach using the whole genome and a diverse set of
compounds allows a comprehensive view of most pharmacological and toxicological questions and
is applicable to other situations such as disease and development.
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Introduction
To increase our understanding of liver biology and to aid
preclinical drug characterization, we have identiﬁed many of
the biological response programs to xenobiotics and drugs in
the liver by measuring RNA abundance changes. Using these
patterns, the similarities and differences in basic biological,
pharmacological and toxicological responses to different
classes of chemicals can be fully characterized.
To achieve these goals, we built a very large liver xenobiotic
and pharmacological response data set. Liver RNA from rats
treated using multiple doses and at several time points with
344 chemicals and drugs belonging to 70 pharmacologic
activity classes and matching vehicle controls was hybridized
to whole genome microarrays. The resulting data set is
composed of 1695 individual animal studies and 5288
microarrays. Coupled to these data are clinical chemistry,
hematology and hepatic histopathology end points selected to
represent data typically collected in pharmacology and
toxicology studies of drug candidates (Ganter et al, 2005).
Others have approached some of these issues using similar
but muchsmallergeneexpression datasetsmostlydesignedto
identify individual signatures, or biomarkers, of one or two
types of phenotypic or pharmacologic end points (Waring and
Ulrich, 2000; Hamadeh et al, 2002; Heinloth et al, 2004; Elrick
et al, 2005; Nie et al, 2006; Slatter et al, 2006). Because of their
limited coverage of different drugs, chemical structures and
pharmacological responses, these studies do not provide a full
description of the xenobiotic response of the liver, and may
suffer from a lack of speciﬁcity due to inadequate representa-
tion of the diversity of drug responses.
This data set presents a data mining investigation of
substantial complexity. Both unsupervised and supervised
(Hastie et al, 2000, 2001; Quackenbush, 2001; Liu and Ringner,
2004) methods can be used for analysis. Because supervised
methods provide a quantitative measure of similarity of new
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www.molecularsystemsbiology.comchemicals to known chemicals, we used them to develop gene
expression signatures (classiﬁers), which are short, weighted
probe lists used to assign a sample to one of two classes (El
Ghaoui et al, 2003; Natsoulis et al, 2005).
The scope of our analysis allows us to derive general
conclusions on the number of phenotypes resolvable by gene
expression and the characteristics of genes and gene expres-
sion changes capable of classifying all resolvable phenotypes.
Inaddition,thesestudiesprovideamethodtoidentifyallofthe
genes that are necessary and sufﬁcient to form a classiﬁer for a
given phenotype. The list of necessary genes allows one to
understand the biology of a phenotype in great detail, as
illustrated using liver ﬁbrosis as an example.
Results
Systematic mining of data set
We systematically divided each phenotype measurement by
severity, dose or time, and attempted to ﬁnd patterns of gene
expression changes that were able to classify the phenotype
and characterize its severity. The phenotypes measured
include histopathological ﬁndings, clinical chemistry and
hematology assay results, and other traditional measures of
health such as body and organ weights. Other phenotypes
include the pharmacological and chemical properties of the
compounds. Samples were separated into two classes, those
that share a given phenotype (positive class) and those that do
not (negative class) (Table I).
A total of 2112 two-class classiﬁcation questions were
submitted to the sparse linear programming (SPLP) algorithm
(Natsoulis et al, 2005), and the results were internally cross-
validated using the split-sample cross-validation procedure
(Table II). In total, 180 signatures met performance cutoffs for
pharmacology-type and toxicity-type signatures (see Materials
and methods); 41 pharmacology signatures had an average
65.4% sensitivity and 99.7% speciﬁcity and averaged 37
probesinlength(range7–70),whilethe139toxicitysignatures
had an average 52.6% sensitivity and 99.2% speciﬁcity and
averaged 79 probes in length (range 27–167). Toxicity
signatures were generally longer than pharmacology signa-
tures, likely due to the complexity of capturing several distinct
biological processes that converge to a common phenotype.
The quality of signatures derived from this systematic
mining effort can be evaluated in several ways. First, each of
the180signatures hasa betterlogoddsratio(LOR)than anyof
ﬁve commonly used preclinical and clinical tests (Figure 1A)
(Kim and Margolin, 1999; Mistry and Cable, 2003; Loy et al,
2004; http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid¼h-
stat1.table.7254). The increased performance is generally
due to the intentional feature of the SPLP algorithm to create
signatures with very high speciﬁcity (El Ghaoui et al, 2003;
Natsoulisetal,2005).Thehighspeciﬁcityavoidsfalse-positive
calls, which, in drug development, could trigger a premature
elimination of a compound or costly secondary testing. We
have developed in addition a modiﬁed algorithm (adjusted
SPLP, ASPLP) that weighs false positives and false negatives
differentlytoobtainsignatureswithenhancedsensitivityanda
slightly reduced speciﬁcity (GRG Lanckriet and G Natsoulis,
unpublished results). Second, the performance metrics are
estimates derived from split-sample cross-validation of the
data and tend to overestimate forward validation performance
obtained on independent data. Using a simulation based on
our own results (Figure 1B), we show that the gap between
these values decreases as the size of the training data set
increases, illustrating that signatures derived from a large
database are more predictive of future performance on
independent data (Michiels et al, 2005). Finally, the conver-
genceofthetwocurves(Figure1B)suggeststhatourdatasetis
sampling a substantial portion of the liver gene expression
repertoire.
Signature redundancy
Many of the classiﬁcation sets were based on phenotypes that
are biologically similar in interpretation, yet based on distinct
end points (i.e. clinical chemistry versus histopathology), so it
was of interest to determine how manyof these 180 signatures
are truly unique. We considered determining the overlap of
signatures by comparing gene composition, class label
similarity and similarity between rules deﬁning the classes.
None of these approaches was ideal as signatures measuring
the same phenotype can have no gene in common (Natsoulis
et al, 2005); looking at class labels does not take into account
outliers that can drastically affect the signature characteristics
and ﬁnally, some phenotypic end points that appear different
areinfactsimilarwhenthefunctionalannotationsofthegenes
are compared. Thus, dissimilarities in class names can hide
biological similarity.
In view of these considerations, we chose a data-derived
deﬁnition of what constitutes a unique signature. Signature
Table I Summary description of the database
Characteristics of the liver xenobiotic and pharmacologic response
data set
Arrays (4941 treated+347 untreated controls) 5288
Treatments (biological triplicate) 1695
Compounds 344
Structure activity classes (SACs)
a 171
Pharmacologic activity classes (ACs)
b 77
Clinical chemistry
c 46
Liver histopathology annotations 57
aDeﬁned by chemists as being distinct structural classes.
bSecond level of a two-step hierarchy. Several structurally distinct but related
SACs are grouped into one AC if they share a target.
cIncludes blood chemistry and hematology assays.
Table II Summary description of the results of the systematic mining
Signature type: Candidates Passing validity criteria
Body and organ weights 25 5
Clinical chemistry
a 477 61
Histopathology 317 65
Therapeutic indication 52
Pharmacology 1241 49
Total 2112 180
aIncludes blood chemistry and hematology assays.
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against all 180 valid signatures were clustered (Figure 2A).
The number of unique signatures present in a set of high-
performing signatures can be deﬁned as the numberof distinct
clusters at a given threshold. At a correlation of 0.6, there are
34clustersofsignatures.Usingahigherthreshold(0.8)derives
55 groups that separate very closely related phenotypes. Using
a lower threshold (0.4) derives 23 clusters. At that level events
that are unique, as deﬁned in the literature, are clustered
together. A correlation of 0.6 ensures that most clusters are
composed of signatures for either a single mode of action or a
single pathological end point and divides the data into groups
that follow both known and unexpected biological relation-
ships. A speciﬁc list of unique non-redundant signatures was
obtained by choosing as representative the signature with the
highest positive predictive value from each cluster (Table III).
In contrast to the supervised method described above, 2D
hierarchical clustering of all 1695 liver experiments by all
genes resolved only a few phenotypes such as HMG-CoA
reductase inhibitors and acute phase responses, while PCA
could resolve no phenotypes. PCA could only resolve
phenotypes when a much smaller data set (o200 experi-
ments) containing experiments with very distinct gene
expression changes was analyzed (data not shown).
To verify that the patterns observed in Figure 2A do not
occur by chance only, we randomized the class assignments
(label permutation) of each of the 180 valid signatures 100
times each and derived and cross-validated a signature for
each permuted label set. Even though the average LOR of the
100 randomized label sets is close to zero for each of the 180
signatures, the maximum LOR rangesbetween1.2 and 5.7 and
averages 2.9, well below the average LOR for the 180 valid
signatures (5.7). The permuted label set signatures are also
much longer (averaging 135 genes) than signatures derived
from real class labels. We chose the signature with the highest
LOR from each set of 100 randomizations and repeated the
clustering experiment described in Figure 2A. Not a single
cluster with more than one member is observed at a
correlation of 0.6, while the highest correlation for a cluster
with atleast twomembersis 0.48(Supplementary information
S12).
Biological relationships between signatures
Beyond its practical use in deﬁning a set of unique signatures,
biologically interestingrelationships arerevealed betweenend
points (Figure 2A). For instance, one large cluster consists of
signatures for PPARa agonists, albumin increase, hepatic
eosinophilia, hypertrophy, HMG-CoA reductase inhibitors and
lipase increase. Both PPARa agonists and HMG-CoA reductase
inhibitors are used to lower serum cholesterol and affect lipid
metabolism. PPARa agonists are known to cause hepatome-
galy and hepatocyte proliferation, and albumin output of the
liver increases as a consequence of hepatomegaly (Peters et al,
1997). Finally, we commonly observed increased blood
albumin concentration as well as hepatocellular eosinophilia
and hypertrophy in both PPARa agonist- and HMG–CoA
reductase inhibitor-treated animals (data not shown).
In another case, certain samples match both the toxicant,
DNA alkylator and the ﬁbrosis and bile duct hyperplasia
signatures (Figure 2B), thus suggesting a biological relation-
ship between cellular damage caused by DNA alkylators and
liver remodeling, bile duct hyperplasia and ﬁbrosis. In our
experiments, most treatments that caused ﬁbrosis also caused
bile duct hyperplasia, and as a consequence, signatures for
ﬁbrosis were well correlated with bile duct hyperplasia
signatures (r¼0.68).
Characteristics of signature genes
Acommonassumption isthat highly weightedsignaturegenes
in valid biomarkers have large amplitudes of regulation in the
75
80
85
90
95
100
02 0 10 40 30 60 50 80 90 70 100
Sensitivity
S
p
e
c
i
f
i
c
i
t
y
LOR=4 LOR=3 LOR=2
180 valid signatures  Five common tests
Ames test
PSA
Chest X-Ray
Mammograph
2
01
2.5
3
3.5
4
4.5
0.2 0.4 0.6 0.8 1.2
Fraction of training dB
A
v
e
L
O
R
Cross-validation Forward validation
Pap smear
Figure 1 (A) Comparing the 180 valid signatures with ﬁve commonly used
tests. The sensitivity and speciﬁcity of the 180 valid signatures are compared
for Pap smears, PSA, mammograph, chest X-ray and Ames test (http://
www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.table.7254; Kim and Margolin,
1999; Mistry and Cable, 2003; Loy et al, 2004). Iso-log odds curves for LOR
equal to 2, 3 and 4 are shown for reference. (B) Modeling the average
performance of signatures derived from databases of increasing size. The
complete data set was split 20 times into a training data set and a forward
validation data set. The training set was further split into half-sized and quarter-
sized training sets. All splits were carried out at the compound level (i.e. all
samples treated with the same compound are either included or not in a given
set), thus modeling a growing toxicology database. The ﬁve signatures with the
largest positive class were chosen for this study out of the set of 180 valid
signatures. Each signature was re-derived and internally cross-validated as
previously described from the 20 different quarter-size, half-size and full-size
training sets. Each signature was also evaluated on the forward validation data
set. The graph represents the average cross-validation and forward validation
results for the ﬁve signatures.
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magnitude of the weight and the amplitude of gene regulation
and between weights and average expression levels in
untreated controls (Supplementary information S2). These
ﬁndings suggest that small changes in expression play
important roles in signatures and speciﬁc liver responses.
A liver xenobiotic response gene set
A total of 1704 probes (representing 1660 distinct genes)
appear at least once in the 34 signatures. Less than 10% (150
probes) account for more than 50% of the sum of impacts
(a measure of importance; see Materials and methods) across
all 34 signatures, while about 25% (400 probes) account for
75% of the sum of impacts (Supplementary information S1).
Thus a small numberof genescontribute disproportionately to
signature performance for all end points.
The average LOR across the 34 signatures is 5.7. Each of the
34 signatures was re-derived, with no additional feature
reduction, using the top 100, 200, 400, 800 and 1600 probes
by impact. A more impartial analysis was carried out by
selecting gene sets from 31 randomly chosen signatures and
evaluating the performance of the other three signatures on
each of the gene sets. The procedure was repeated 10 times,
evaluating the performance of a different set of three
signatures eachtime.The twocurvesforaverageLOR,training
on genes from all or training on genes from all but three
signatures, are statistically indistinguishable (Figure 3) and
form a rapidly rising curve which reaches the performance of
the full set at 200 probes and exceeds the performance of all
genes at 400 probes. The average performance of the 34
signatures derived from three separate random gene sets of
equal size drawn from the array is lower. The entire procedure
was repeated using permuted label sets (Supplementary
information S12). In this case, the two impact-based curves
do not separate from the curve based on random gene choice.
Clearly, a subset of genes selected based on importance in
signature performance performs better than the whole. The
performance of any classiﬁcation algorithm can decrease in
the presence of a large excess of lower information content
variables (genes), ultimately overwhelming the classiﬁcation
algorithm. SPLP is rather insensitive although not completely
immune to this effect (Natsoulis et al, 2005). In addition, pre-
selection of genes based on probe variance or highest signal
intensity had little effect on the average LOR, whereas
pre-selection based on the average log ratio across the positive
class and statistical signiﬁcance of fold change reduces
signature performance (Supplementary information S2).
This analysis suggests that the genes selected by the impact
metric are of general applicability, and just a small portion, by
themselves, can characterize a large fraction of liver response
to xenobiotics. We further characterized the utility of the
small gene set to derive signatures for a biological event
distinct from xenobiotic exposure, caloric restriction. The 200
gene set was far superior to a random selection of genes in
classifying the response to caloric restriction (Supplementary
information S10).
Gene composition of the xenobiotic response
gene set
Giventhat just 200 probes out of the 1704 probesin the unique
34signaturescancreatevalidsignaturesforadiversesetofend
points, this set would be expected to contain many genes
involved in liver xenobiotic metabolism, pharmacology and
response to tissue injury. The probes were ranked by the sum
of their impact across all signatures and examined for
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Figure 2 Determination of a unique set of liver signatures. (A) A scalar product by treatment heat map, expressing the scores of all expression proﬁles against all
signatures. (B) A blowup of regions a and b of (A) is shown. Negative values were set to zero and the resulting positive SP table was submitted to unweighted average-
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Supplementary information S8). We sought to increase the
sensitivity of detecting GO term enrichment by analyzing
successive portions of that ranked list as some terms, only
enriched in the very top of the list, might not appear
signiﬁcantly enriched in the entire list. GO terms associated
with many of the liver’s functions are enriched in the ﬁrst
windows of analysis (Figure 4), such as the terms cytochrome
P450 and microsome, two partially overlapping GO terms
(Supplementary information S9), reﬂecting the importance of
cytochrome P450s in xenobiotic metabolism (Ioannides,
2002). The term fatty acid metabolism, comprising genes such
as fatty acid synthase, enoyl-CoA hydratase, acyl-CoA synthe-
tase among others is also enriched. The liver is a major site for
fatty acid and lipid metabolism, and several major classes of
compounds present in the database (statins, ﬁbrates, glita-
zones, estrogen receptor modulators and others) affect lipid
synthesis and degradation. Terms such as feeding behavior
(including genes such as orexin and glucagon) and potassium
ion transport and elevation of cytosolic calcium ion concen-
tration suggest that genes belonging to these categories are
also involved in xenobiotic responses but are less important
than cytochrome P450 and fatty acid metabolism which peak
earlier.
Identiﬁcation of complete gene sets capable of
forming a classiﬁer
We have previously observed that several signatures for the
same end point can be derived with no gene in common
(Natsoulis et al, 2005). Therefore, it was of interest to
determine how many different genes are capable, in various
combinations, of yielding a signature with a performance
exceeding a certain threshold for a given classiﬁcation
question. Such a gene set could be considered a necessary
gene set (NGS) because novalid signature can be derivedfrom
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minus the NGS). To determine the NGS for each of the 34 end
points described above (Table III and Supplementary informa-
tion S11), all genes were submitted to the signature-generating
algorithm initially. If a valid signature was obtained, the
highestimpactsignatureprobes,accountingforX90%oftotal
impact, were removed from the set of all probes and the
resulting stripped set was resubmitted to the algorithm. The
cycle was repeated until the performance of the signatures
dropped below a chosen threshold (for this experiment LOR
X4); we call this procedure ‘stripping’. Some signatures, such
as spleen weight decrease and periportal lipid accumulation,
continue to yield valid signatures even after more than 20
cycles of stripping. The performance of other signatures such
as monocyte increase and periportal hypertrophy rapidly
decays after one or two cycles. Examination of the genes in
these stripped signatures for each type suggests that in the
former case, a large number of genes belonging to different
pathways are sufﬁciently characteristic of the end point in
question to yield a valid signature. In the latter case, just a few
genes have the ability to diagnose the phenotype and once
removed from consideration, no other gene can substitute.
Liver ﬁbrosis
To illustrate the value of the NGS gene list formed by the
stripping procedure, we chose the liver ﬁbrosis signatures for
detailed analysis (SV0650143R5RU, Table III). Chronic liver
ﬁbrosis can ultimately result in liver failure and is a signiﬁcant
risk factor for livercancer, and remains difﬁcult to prevent and
treat (Takahara et al, 2006; Iredale, 2007). Better under-
standing of the biological responses during development of
ﬁbrosis has emerged via studies using multiple experimental
model systems (Huang et al, 2004; Jiang et al, 2004;
Utsunomiya et al, 2004; Takahara et al, 2006; Gnainsky et al,
2007;Iredale,2007)andgenome-widecharacterizationofgene
expression changes as described here.
Hepatic ﬁbrosis commonly occurs following injury from a
variety of insults, including drugs and toxicants, and is
accompanied by an inﬂammatory response triggered by
Kupffer cells, resident monocytes and other types of immune
cells. Hepatic stellate cells (HSCs) are normally quiescent;
upon hepatocyte injury, however, HSCs are activated by
inﬂammation and differentiate into myoﬁbroblast-like cells
that can proliferate and migrate. HSCs and periportal
ﬁbroblasts repair hepatic injury by secreting extracellular
matrix proteins such as collagen, whose synthesis is promoted
by the ﬁbrogenic cytokine TGFb (Ramm et al, 2000).
Gene-type enrichment in signatures reveals
pathways and processes activated by
pharmacology or pathology
The1380uniqueprobes(SupplementaryinformationS11)that
were present in all stripped ﬁbrosis signatures that exceeded
LOR¼4 are statistically enriched (P-value o0.05) in GO terms,
such as cell–matrix adhesion, amino-acid transporter activity,
fatty acid biosynthetic process, cellular defense response,
chemokine activity, organic anion transporter activity, sulfate
transport, positive regulation of transcription and carbo-
hydrate transport, most of which are affected during injury
and subsequent ﬁbrosis and bile duct hyperplasia (Figure 5A).
Other terms such as serotonin receptor activity, sensory
perception and brain development were enriched at P-values
o0.001, indicating that local innervation and paracrine
regulation of liver functions are remodeled during ﬁbrosis.
Many of these enrichments are not observed until the later
signature cycles (cell–matrix adhesion and serotonin trans-
porter activity, for example) and could be missed with more
conventional methods of analysis.
Downregulation of a number of liver-speciﬁc genes may
signal a loss of function of and/or an actual loss of the major
parenchymal cells in the liver, hepatocytes, which comprise
80% of the normal liver cell population. Genes that are
preferentially downregulated include those that are involved
in amino-acid metabolism, organic anion and amino-acid
transport and metabolism, and several sulfotransferases and
cytochrome P450s (Figure 5B).
Genes that are preferentially upregulated in contrast include
those involved in cell adhesion, cytoskeleton organization,
cell–cell signaling, proliferation, xenobiotic metabolism and
the immune response. Molecules that are upregulated
induce or promote cell adhesion (PDGFa, endothelin 1,
cd36, osteoblast-speciﬁc factor and procollagen C-endopepti-
dase enhancer) and remodeling of the actin cytoskeleton
(Flna, Tekt1, Krt2-7 and Cappa1). Both PDGFa and endothelin
1 promote activation of HSCs and consequently ﬁbrosis (Eng
and Friedman, 2000; Iredale, 2007). In total, 84 of 137 probes
that averaged twofold or more upregulation had low ex-
pression in the liver (average log signal intensity o 0.3;
P-value¼8.8 10
 7). Many of these genes are those upregu-
latedin rare cell types that areactivatedduring liver injuryand
ﬁbrosis, such as HSCs and Kupffer cells (Figure 5B).
TGFb1, which is a strong promoter of collagen production
and ﬁbrosis, was itself unchanged on average. TGFb1 must be
proteolytically processed before becoming active (Zhu and
Burgess, 2001) and thus there may be a change in conditions
that favor processing of latent TGFb1 during liver injury.
Evidence that TGFb1 is exerting an active inﬂuence includes
the induction of both TGFb1-induced transcript 1 and
follistatin. Follistatin is an antagonist of activin, a growth
factor that is a member of the TGF superfamily, and may
modulate TGF action (Matzuk et al, 1995).
Activated HSCs produce collagen, which is deposited as part
of the remodeling of the extracellular matrix during ﬁbrosis.
Expression of collagen at the sites of injury correlates with
induction of ﬁbrosis and scarring (Leveille and Arias, 1993;
Alcolado et al, 1997; Gabele et al, 2003). Seven different genes
encoding collagen molecules were part of the NGS, including
procollagen type 1 a1 (upregulated about twofold on average
across the positive class), the primary molecule in collagen I
(data not shown).
The NGS analyses for all 34 unique signatures is summar-
ized in Supplementary information S11. Similar insight into
biology can be obtained through these analyses. For example,
the HMG CoA reductase inhibitor signature NGS is enriched
in cholesterol biosynthesis genes, reﬂecting the mechanism
of action of these drugs. In addition, this signature was
derived from high-dose treatments that caused liver injury.
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observed, a possible reﬂection of the liver response to injury.
Discussion
The concept of the connectivity map was recently introduced,
whereby a set of signatures is compared to a reference
database of gene expression proﬁles obtained from com-
pound-treated cell lines (Lamb et al, 2006). The authors show
that close examination of gene expression proﬁles correlated
and anticorrelated with a given signature provides insights
into the multiple modes of action of certain compound classes
and into the multiple biological mechanisms underpinning the
phenotype of interest (Lamb et al, 2006). Here, we explore a
much larger xenobiotic response database in an in vivo model.
The breadth of the database and the systematic nature of the
methodology allow us to derive a number of observations of
general interest. (1) We have developed methods to identify
biologically synonymous end points; these synonymous end
pointsuncoveredunexpectedassociationsbetweenapparently
unrelated phenotypes. Using this method, we identify signa-
tures (classiﬁers) for 34 distinct end points. (2) We show that
signaturegenes arenot appreciablyenriched in genes showing
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also show that aggressive gene pre-selection by amplitude of
expression change or statistical signiﬁcance reduces classiﬁer
quality. (3) We show that a small number of genes (B200) is
sufﬁcient to classify all unique phenotypic end points in the
liver. (4) We show that this limited gene set involves many
genes in the xenobiotic response repertoire. (5) Finally, we
show that a large data set encompassing a wide variety of
toxicological and pharmacological activities yields signatures
with higher performance.
Our approach also identiﬁes examples of very different
signatures for a single end point. Similar results have been
reported before and have often been regarded as problematic
for the studies themselves or of the ﬁeld in general (Michiels
et al, 2005). Here, we describe a formal method to identify all
thegenescapableofdeﬁningaclassiﬁerforagivenphenotype,
at a chosen quality threshold. These lists of necessary genes
form a ranked list of the genes involved in a particular
phenotypeandcanbeusedtocharacterizethegeneexpression
changes and thus infer biological changes that underlie a
phenotype. Because the NGS includes all potential genes that
could be used as part of a diagnostic test, a deﬁnition of
the NGS for a particular phenotype or disease provides
robust intellectual property and a barrier to entry for others
attempting to build diagnostics for the same phenotype.
The liver ﬁbrosis NGS provides insights into the biological
pathways involved in the progression from liver injury to
ﬁbrosis. We show that xenobiotic insult leads to loss of certain
gene expression apparently secondary to hepatocyte cell death
through necrosis and apoptosis and leads to the upregulation
of weakly expressed genes, probably due to activation and
expansion of less abundant cell types, such as HSCs and
Kupffer cells.
This study illustrates that a comprehensive approach can
distill a complex and broad issue to a deﬁnable set of answers,
increase our knowledge and develop useful signatures and
diagnostics. Using a similar approach would better character-
izeothermodelsystemsandmolecularphenotypesunderlying
disease processes and lead ultimately to clinically useful
diagnostic markers.
Materials and methods
Rat liver xenobiotic and pharmacology database
The construction of the database was previously described in detail
(Ganter et al, 2005). We focus here on the liver portion of the data set.
In total, the data set was comprised of 5288 individual animal studies
(arrays). The array data used in this study have been deposited in the
Gene Expression Omnibus (GEO accession no. GSE8858). Microarray
analysis was performed on liver mRNA using CodeLink Rat UniSet 1
Bioarrays (now provided by Applied Microarrays, Tempe, AZ, USA)
with analysis restricted to 8565 probes and about 7700 individual
genes. Coupled to these data are the blood clinical chemistry,
hematology and histopathology ﬁndings typically measured in
pharmacology and toxicology studies of new chemicals and drugs
(Tables I and II and Supplementary information S3 describe the
dimensions and contents of the data set). Taken together, the RNA
abundance measurements and the phenotypic measurements consti-
tute a uniform data set, which we have explored using supervised
mining methods using classiﬁcation rules established as described
below.
Deﬁnitions
During the course of this study we employed several widely used
concepts, and a few novel metrics, which are deﬁned here to increase
clarity.Treatment:abiologicaltriplicategroupofsamplesderivedfrom
animals treated with the same dose, for the same time and with the
same compound. Upregulated, downregulated: indicate changes in the
steady-state level of expression of a RNA in the liver, we note that
tissues are composed of several cell types and changes may reﬂect
multiplication, activation, inactivation or death of cell populations, in
addition to selective RNA degradation, or changes in primary
transcription rates. Orthogonal data: data describing samples that
are not gene expression data; for example, clinical chemistry,
hematology-, histopathology-, pharmacology- and literature-derived
annotations. True positive (TP): samples for which the biomarker
indicates the sample is positive and the orthogonal data indicate the
sampleispositivefor thephenotypeunderinvestigation.Truenegative
(TN): samples for which the biomarker indicates the sample is
negative and the orthogonal data indicate the sample is negative for
the phenotype under investigation. False negative (FN): samples for
which the biomarker indicates the sample is negative and the
orthogonal data indicate the sample is positive. False positive (FP):
samples for which the biomarker indicates the sample is positive
and the orthogonal data indicate the sample is negative. Log ratio:
always refers to log10 ratio of mean signals of treated samples
to vehicle treated controls for the gene in question. Sensitivity: sensi-
tivity¼TP/(TPþFN). Speciﬁcity: speciﬁcity¼TN/(FPþTN). Positive
predictive value (PPV): PPV¼TP/(TPþFP). Log odds ratio (LOR):
LOR¼ln(((TPþ0.5)(TNþ0.5))/(FPþ0.5)(FNþ0.5)). The scalar pro-
duct (SP): deﬁned for a treatment as SP¼Swixi b, where wi is the
weight for gene i and xi is the log10 ratio for gene i; the sum is over all
genes of the signature. Note that the list of genes and weights is the
output of the SPLP algorithm. Impact: the impact of a gene in a
signature is computed by multiplying the average log ratio x for that
gene across the positive class deﬁned in the signature deﬁnition (see
below) by the weight w of that gene in the signature. The total impact
of the gene is that value, minus the equivalent value calculated for the
negative class. Gene list and GO analysis: or examinations of lists of
genesforenrichment ofvariousterms;enrichment is calculatedby use
ofFisher’sexacttestandoftenexpressedastheP-valueor log10 ofthe
P-value for the particular term(s).
Rule types for class deﬁnition
The rules were implemented using the SQL query language according
tothefollowinglogicalsteps.First,the‘universe’ofproﬁlesrelevantto
the two-class classiﬁcation question was deﬁned. The universe could
be further restricted based on dose, time or both considerations.
Proﬁles outside the universe were not considered further. Next the
universe was split into three classes: the positive class, the negative
class and the excluded class. The positive class was usually deﬁned as
the set of samples sharing a particular property, while the negative
class was often deﬁned as the remainder of the universe. A portion of
the universe was sometimes assigned to an excluded class when the
true phenotype might not be known for some samples because they
were not assayed, or they were assayed but assay values were missing
or uncertain. Alternatively, when classes were deﬁned based on a
continuous assay value, samples were often ranked, by fold change or
P-value versus control, for example. The positive and negative classes
werethendeﬁnedastheextremes(topone-thirdandbottomone-third,
for example) of this distribution and the intermediate samples were
assigned to the excluded class. This had the advantage of training
neither for nor against samples with intermediate values. Most of the
clinical chemistry and hematology rules were structured in this
manner since these values were continuous. In these cases, derivation
of signatures along the variable distribution was often systematically
explored. For example, signatures were systematically derived for a
particularclinicalvaluefromtreatmentswithfoldchangesof100-,30-,
10-, 3-, 1.5- and 1.1-fold; similar systematic schemes were applied as
appropriate to ranked lists, P-values, ridit scores and other metrics
indicating intensity. These systematic studies often revealed how the
phenotype changed with intensity.
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impose chemical diversity on the training set, thereby broadening the
applicability, we imposed minimum class sizes. A minimum class size
was imposed for both the positive and negative classes and for all rule
types. We used split-sample cross-validation across 20 randomly
selected splits to estimate the performance of the signature. We
uniformly applied a split ratio of 60% training and 40% test, which in
casesofapositiveclasssizeequalto6correspondedto3.6trainingand
2.4 test, or after rounding, 3 positive samples in the training set and 3
in the test set. Imposing a lower limit of six experiments in the positive
class ensured that a minimum number of 6!/(3!*3!)¼20 distinct splits
of the positive class were possible. The minimum negative class size
was set at 44 so that the sum of minimum sizes for both classes
comprised at least 50 samples. The larger minimum class requirement
for the negative class was intended to ensure diversity within the
negative class, so that the resulting signature was capable of
discriminating between the ‘phenotype of interest’ and a large variety
of other effects. A minimum of three distinct chemicals was also
imposed on the positive class to ensure that the signatures recognized
a general property of the class and not idiosyncratic characteristics of
an individual compound. Additionally, for clinical chemistry and
hematology and histopathology signatures, we required that the
compounds used in the positive class treatments belong to three
separate activity classes. Again, this was to ensure that the resulting
signature is characteristic of the common pathology and not of an
individual compound class. The logical steps described above were
combined and automated to generate rule sets that could be
categorized by the type of data deﬁning the positive class as distinct
from most of the other treatments within the database.
The systematic mining, using the restrictions and procedures
mentioned, resulted in 2112 signature-derivation rules. The positive
classes of these signatures averaged 36 treatments and included an
average of 14 drugs from 11 classes per signature, and the negative
class averaged 754 treatments and included an average of 270 drugs
from 63 activity classes. Thus, the diversity of the treatments, drugs
and activity classes was very large. Examples of the complete list of
2112 rules are presented by rule type for the activity class, structure
activity class, pharmacology, clinical chemistry, hematology, histo-
pathology rules and the body-and-organ weight rules (Supplementary
information S4). The list of histopathology annotations and of the
clinicalchemistryandhematologyassays onwhichthe rulesare based
is presented (Supplementary information S3). Full Excel
s ﬁles
containing all of the rules also accompany this paper. The compound
classiﬁcation in terms of activity class and structure activity class as
wellastheclasslabelsforthe34uniquesignaturesisshowninTableIII
and other characteristics of the set of 34 unique signatures can be
found in Supplementary information S5, S6, S7 and S8.
Signature derivation and cross-validation
The classiﬁcation algorithm used was the SPLP algorithm (El Ghaoui
et al, 2003; Natsoulis et al, 2005). We note that this algorithm makes
use of the mean log ratio and the standard error of the mean within
each biological triplicate experiment, thus accounting for variabilityof
measurements in classiﬁer construction. In all cases, probes were
eliminated for missing data (for the positive class if any data were
missing; or for the negative class if 45% missing values). Missing
probes occurred because of array technical failures, values below
threshold and several other less common technical reasons. For
computational speed consideration, probe pre-selection (feature
reduction) byvariancewasused for those systematic mining signature
derivation runs, which aimed to characterize all possible drug
signatures, 2112 derivations in total (Tables I and II).
Split-sample cross-validation
In all cases, a 60/40 split-sample procedure was applied and the
performance was reported as the average of the test results for 20
random partitions of the data (Simon et al, 2003; Allison et al, 2006;
Varma and Simon, 2006). In cases where the sample class identities
(labels) were set according to the properties of the compound
(structure activity class, activity class and pharmacology signatures)
the treatments were split by compounds. Splitting by compounds
placedalldose–timecombinationsoftreatmentsforagivencompound
either in the training or in the test set. This avoidedsituationsinwhich
a signature could be trained on samples treated with multiple dose–
time combinations of a compound and evaluated on other dose–time
combinationsofthesamecompound.Evaluationwasperformedatthe
level of the treatment. We refer to this modiﬁed cross-validation
procedure as split by compound, count by treatment. In cases where
the labels were set according to the properties of the sample (e.g.
signatures for histopathology and clinical chemistry end points where
dose level and/or time point are critical to development of the
phenotype), both the partitioning and the evaluation were carried out
atthelevel ofthesample;werefertothis cross-validationprocedureas
split by treatment, count by treatment.
Validity criteria
We deﬁned two different validity cutoffs for signatures based on their
anticipated use and the sensitivityof the expected user groups to false-
positive or false-negative errors. A speciﬁcity X95% and sensitivity
X50% was used for signatures assessing pharmacology, and
speciﬁcity X98% and sensitivity X40% for signatures classifying
toxicity end points.
Liver xenobiotic response gene set
An impact table for all genes appearing in the 34 unique signatures
recomputed without gene pre-selection is presented (Supplementary
information S8). Genes were sorted according to the sum of impacts
across all signatures. This sorted list is referred to in the text as the
impact-based list. The top 200 genes fromthis list are referred to as the
liver xenobiotic response gene set.
Identiﬁcation of NGSs
For a given end point, all available gene variables (i.e. no feature
reduction) were submitted to the SPLP algorithm. If, upon cross-
validation, the performance of the resulting signature exceeded
LOR¼4, the highest impact genes participating in the signature were
set aside from the data set. The signature was re-derived and the
procedure was repeated until the performance of the signature
dropped below LOR¼4. The union of all the set-aside gene sets was
the NGS. We have observed that on average less than half the genes
contribute more than 90% of the impact in any given signature. To
focusthealgorithmonthegenescontributingmosttothesignature,for
eachcyclegeneswererankedbyimpact,andthehighestrankedgenes,
accounting for at least 90% of the total impact, were designated as the
most importantgenes in the signature and set aside. GO analysis of the
stripped gene set was performed as follows: genes were arranged in
order of stripping cycles. GO analysis was performed on a series of
overlapping windows of 50 genes with increments of 25. GO term
enrichment was calculated for each window and for each GO
term using Fisher’s exact test.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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